Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1800315 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $29.21Day +3.11%Mkt cap $1.8BOff 52W high −16.3%Vol (1Y) 92.4%
Daily closing price, split-adjusted to the current basis; 0.4y shown of 89 bars on file. Sampled to 89 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.6% of sh out |
| Days to cover8.1d |
| 13F net flow (QoQ)+24.19% |
| Top-10 13F concentration69.5% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$235.1M |
| ROE−163.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
No return windows available for DMRA.
| Ann. volatility (1Y)92.4% |
| Ann. volatility (3Y)92.4% |
| Sharpe (1Y)0.86 |
| Sharpe (3Y)0.86 |
| Max drawdown (1Y)−31.2% |
| Max drawdown (3Y)−31.2% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 9.0M | $234M | 15.00% | +3686.7% |
| Fairmount Funds Management LLC | 8.7M | $226M | 14.45% | new |
| Avoro Capital Advisors LLC | 3.8M | $98M | 6.27% | new |
| Venrock Adviser, LLC | 3.6M | $93M | 5.98% | new |
| FCPM III SERVICES B.V. | 2.4M | $63M | 4.05% | new |
| RA CAPITAL MANAGEMENT, L.P. | 2.4M | $62M | 3.98% | new |
| JANUS HENDERSON GROUP PLC | 2.4M | $61M | 3.92% | +135765.2% |
| VIKING GLOBAL INVESTORS LP | 2.3M | $60M | 3.83% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.62 | — | — | — |
| 2025-09-30 | 2025-11-06 | −$2.36 | — | — | — |
| 2025-06-30 | 2025-08-05 | −$2.60 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$1.92 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
